Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 11/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27815171 | 0.84 | KDM4E (0.70) | KDM4EHPGDMAPTALDH1A1MEN1 | |
| SCHEMBL12907922 | 0.84 | KDM4E (0.70) | KDM4EHPGDMAPTALDH1A1MEN1 | |
| SCHEMBL2201945 | 0.77 | EGLN1 (0.66) | KDM4EHPGDALDH1A1HSD17B10PSMD14 | |
| SCHEMBL27934811 | 0.77 | KDM4E (0.68) | KDM4EHPGDMAPTALDH1A1MEN1 | |
| SCHEMBL16598147 | 0.76 | HPGD (0.61) | KDM4EHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL7375869 | 0.76 | PDE4A (0.61) | KDM4EHPGDKMT2AGAA | |
| SCHEMBL2751542 | 0.76 | ALDH1A1 (0.72) | KDM4EHPGDMAPTALDH1A1MEN1 | |
| SCHEMBL2750373 | 0.76 | KDM4E (0.63) | KDM4EHPGDMAPTALDH1A1MEN1 | |
| SCHEMBL2401416 | 0.76 | HPGD (0.71) | KDM4EHPGDMAPTALDH1A1MEN1 | |
| SCHEMBL18541884 | 0.75 | PSMD14 (0.74) | KDM4EHPGDMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406226-B1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| EP-2406226-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-8084470-B2 | Substituted nicotinamide compounds and uses thereof | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| WO-2010102809-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2188258-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICAL PRODUCTS | Grünenthal GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009036938-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICAL PRODUCTS | Grünenthal GmbH (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | NNT, NAMPT, NADK | KDM4E 2156/4885HPGD 11/4885MAPT 354/4885 |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | KDM4E 1407/4885HPGD 651/4885MAPT 216/4885 |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | KDM4E 708/4885HPGD 508/4885MAPT 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.